MAIA Biotechnology (MAIA) Targets 100-Patient Enrollment by Year-End for Phase 3 Lung Cancer Trial

MAIA Biotechnology (NASDAQ: MAIA) said on June 5, 2026 it is advancing a Phase 3 trial for its lead drug ateganosine in advanced non-small cell lung cancer, setting a target to enroll 100 patients by Dec. 31, 2026. The THIO-104 study follows positive Phase 2 survival data that supported moving into late-stage testing. The clinical-stage biotech is expanding its trial sites to accelerate recruitment. Ateganosine is a first-in-class telomere-targeting agent that binds to telomeres to disrupt cancer cell replication. No financial details were provided. The enrollment goal marks a key development milestone for the company as it seeks to validate a novel NSCLC treatment approach.